Research Notes: Ozempic Losers (Part I)

Potential shorts, and possible longs, as GLP-1s continue to impact the market

Highlights:

• We provide quick updates on a few past deep dives.

• One stock in the gaming space looks like the absolute best play on GLP-1s treating gambling addiction.

• Energy-based aesthetics stocks have their own issues, but at the lows there is an intriguing, if risky, contrarian case.

• Thanks in part to Ozempic’s potential in treating kidney failure, Outset Medical has been one of the worst stocks in the market. Aggressive traders can see OM as a potential short to zero.